Prosight Management’s Regenxbio RGNX Stock Holding History

Prosight Management’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-200,000	Closed	-$1.68M	–	42
2026 Q1	$1.68M	Buy	+200,000	New	+$2.1M	0.27%	37

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Prosight Management's RGNX Position: Q2 2026 in Review

Prosight Management sold out of Regenxbio (RGNX) in Q2 2026, closing a stake of 200,000 shares — an estimated $1.68M sold.

Prosight Management first reported a position in RGNX in Q1 2026 and held it in 1 quarter. The position peaked at $1.68M in Q1 2026. 165 funds tracked by Wall St. Rank hold RGNX as of Q2 2026.

Prosight Management reported no remaining Regenxbio position as of Q2 2026 after selling out during the quarter.
Prosight Management sold 200,000 Regenxbio shares in Q2 2026, an estimated $1.68M.
Prosight Management first reported a position in Regenxbio in Q1 2026 and held it in 1 quarter.
Prosight Management's Regenxbio position peaked at $1.68M in Q1 2026.
165 funds tracked by Wall St. Rank held Regenxbio as of Q2 2026.

Based on Prosight Management's 13F filing for Q2 2026, filed 14 Aug 2026.